5 completed, 4 unknown. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Unknown 4 |
| Phase 2 | 2 | Completed 2 |
Follow Lead: new trials by email Literature Review of Lead trials Research Report on Lead
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 20 | 2025-05-09 | 2025-08-29 |
| Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State DA-1229_01 5/1000mg (Before), DA-1229_01 5/1000mg (After) - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 34 | 2023-03-30 | 2023-02-22 |
| Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting State DA-1229_01 5/1000mg (Before), DA-1229_01 5/1000mg (After) - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 40 | 2023-03-25 | 2023-02-22 |
| Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After) - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 40 | 2023-03-18 | 2023-02-22 |
| Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After) - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 34 | 2023-03-17 | 2023-02-22 |
| Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL - HIV Infections | Phase 1 | Completed | ViiV Healthcare | 138 | 2020-07-31 | 2026-05-29 |
| Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 32 | 2017-11-29 | 2026-09-17 |
| Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer erlotinib - EGFR-Mutant Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 53 | 2013-10-15 | 2018-11-13 |
| Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2 - Carcinoma, Pancreatic Ductal | Phase 1 / Phase 2 | Completed | Silence Therapeutics GmbH | 29 | 2013-03-01 | 2016-03-11 |
Adenocarcinoma (1) · Brain Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Glioblastoma (1) · HIV Infections (1)
Dong-A ST Co., Ltd. (4) · Atea Pharmaceuticals, Inc. (1) · Case Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Silence Therapeutics GmbH (1) · ViiV Healthcare (1)
South Korea (4) · United States (4) · Germany (1) · New Zealand (1)
Dirk Strumberg, Prof.Dr.med. (1) · Helena Yu, MD (1) · Tiffany Hodges, MD (1)